Version 1
: Received: 20 July 2021 / Approved: 22 July 2021 / Online: 22 July 2021 (07:48:33 CEST)
How to cite:
Al Khoury, C.A.; Nemer, N.; Tokajian, S.; Nemer, G. Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints2021, 2021070506. https://doi.org/10.20944/preprints202107.0506.v1
Al Khoury, C.A.; Nemer, N.; Tokajian, S.; Nemer, G. Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints 2021, 2021070506. https://doi.org/10.20944/preprints202107.0506.v1
Al Khoury, C.A.; Nemer, N.; Tokajian, S.; Nemer, G. Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints2021, 2021070506. https://doi.org/10.20944/preprints202107.0506.v1
APA Style
Al Khoury, C.A., Nemer, N., Tokajian, S., & Nemer, G. (2021). Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints. https://doi.org/10.20944/preprints202107.0506.v1
Chicago/Turabian Style
Al Khoury, C.A., Sima Tokajian and Georges Nemer. 2021 "Beauvericin: The Journey of a Pesticide into a Humanized Drug" Preprints. https://doi.org/10.20944/preprints202107.0506.v1
Abstract
Drug discovery has been initially attributed to coincidence or trial and error where the traditional approach was complex, lengthy, and expensive. Conventional drug discovery methods require the costly random screening of synthesized compounds or natural products. Another downside for this approach is the wide dependency on the experimental use of animals for in vi-vo testing. Currently, in silico modeling has become a vital tool for drug discovery and repurposing, and molecular docking is being used to find the best matching between a ligand and a molecule. Practical application of in silico docking will predict the biomolecular interactions between the drug and the target host. Beauvericin (BEA) is an emerging mycotoxin produced by the entomopathogenic fungus Beauveria bassiana. Originally investigated for its pesticide capability, BEA is now considered as a molecule of interest for its potentially diverse biotechnological applications in the pharmacological industry and the field of medicine. In this manuscript, we will provide an overview of the repurposing of BEA into a potentially superior therapeutic molecule in a broad range of diseases. Furthermore, considerable attention has been given to the fundamental role of in silico techniques to i) further investigate the spectrum of this secondary metabolite and ii) elucidate the pathways of BEA for its promising therapeutic action
Keywords
Drug repositioning; Molecular modelling; Beauvericin
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
